Loading market data...
Latest Top News
Show more
Biocon Pharma Nears US Market Breakthrough With FDA Tentative Approval
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has achieved a significant regulatory milestone by securing tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg. This rifamycin antibac...
Stay Ahead – Explore Now! Jindal Steel & Power Faces Q4 Headwinds, Announces ₹2 Dividend to Keep Spirits High






